Back
Globus Medical 10K Form
Sell
20
GMED
Globus Medical
Last Price:
50.43
Seasonality Move:
2.48%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-07 | 10Q | GMED/Globus Medical Quarterly |
2023-08-03 | 10Q | GMED/Globus Medical Quarterly |
2023-05-04 | 10Q | GMED/Globus Medical Quarterly |
2022-11-08 | 10Q | GMED/Globus Medical Quarterly |
2022-08-04 | 10Q | GMED/Globus Medical Quarterly |
2022-05-10 | 10Q | GMED/Globus Medical Quarterly |
Receive GMED News And Ratings
See the #1 stock for the next 7 days that we like better than GMED
GMED Financial Statistics
Sales & Book Value
Annual Sales: | $1.57B |
---|---|
Cash Flow: | $81.79M |
Price / Cash Flow: | 34.45 |
Annual Sales: | $29.32 |
Price / Book: | 1.69 |
Profitability
EPS (TTM): | 1.17000 |
---|---|
Net Income (TTM): | $122.87M |
Gross Margin: | $1.02B |
Return on Equity: | 4.41% |
Return on Assets: | 3.64% |
Globus Medical Earnings Forecast
Key Globus Medical Financial Ratios
- The Gross Profit Margin over the past 15 years for GMED is 65.05%.
- The Selling, General & Administrative Expenses for GMED have been equal to 41.02% of Gross Profit Margin.
- The Research & Development expenses have been 7.91% of Revenue.
- The Interest Expense is -11.22% of Operating Income.
- The Net Earning history of GMED is 7.83% of Total Revenues.
- Per Share Earnings over the last 15 years have been positive in 8 years.
Globus Medical Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | GMED |
CUSIP: | 379577 |
Website: | globusmedical.com |
Debt
Debt-to-Equity Ratio: | 0.1 |
---|---|
Current Ratio: | 4.88 |
Quick Ratio: | 2.61 |
Price-to-Earnings
Trailing P/E Ratio: | 46.53 |
---|---|
Forward P/E Ratio: | 15.07 |
GMED Technical Analysis vs Fundamental Analysis
Sell
20
Globus Medical (GMED)
is a Sell
Is Globus Medical a Buy or a Sell?
-
Globus Medical stock is rated a Sell
The current Globus Medical [GMED] share price is $49.79. The Score for GMED is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.